SCHEMBL4975262

SCHEMBL4975262

CCOC(=O)C1C(=O)CCc2cc(-c3ccc4c(c3)OCO4)ccc21

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HSD17B10 Q99714 3/20 0.44
KDM4E B2RXH2 2/20 0.44
TP53 P04637 1/20 0.44
SMN1; SMN2 Q16637 1/20 0.44
ALDH1A1 P00352 5/20 0.44
NPC1 O15118 2/20 0.44
RAB9A P51151 2/20 0.44
CYP1A2 P05177 1/20 0.44
CYP3A4 P08684 1/20 0.44
CYP2D6 P10635 1/20 0.44
CYP2C9 P11712 1/20 0.44
CYP2C19 P33261 1/20 0.44
HTT P42858 1/20 0.44
PRKCI P41743 1/20 0.43
PRKCZ Q05513 1/20 0.43
POLB P06746 3/20 0.42
KMT2A Q03164 2/20 0.42
MEN1 O00255 1/20 0.42
MAPT P10636 1/20 0.42
HPGD P15428 2/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4974228 0.83 MEN1 (0.41) HSD17B10KDM4ETP53SMN1; SMN2ALDH1A1
SCHEMBL4970905 0.82 ATM (0.43) RAB9AKMT2AMEN1
SCHEMBL4972012 0.81 ALDH1A1 (0.41) HSD17B10KDM4ETP53SMN1; SMN2ALDH1A1
SCHEMBL4970522 0.79 HRH3 (0.40) CYP3A4CYP2C9
SCHEMBL4972770 0.76 TDP2 (0.52) HSD17B10KDM4ETP53SMN1; SMN2ALDH1A1
SCHEMBL4740754 0.76 MAPK1 (0.44) HSD17B10KDM4EALDH1A1HTTPOLB
SCHEMBL4973505 0.75 KDM4E (0.46) KDM4EALDH1A1HTTPOLBKMT2A
SCHEMBL4970874 0.73 GRM5 (0.39) HSD17B10KDM4EALDH1A1CYP1A2CYP3A4
SCHEMBL4969649 0.73 HPGD (0.43) HSD17B10KDM4ETP53SMN1; SMN2ALDH1A1
SCHEMBL2995600 0.71 MAPT (0.67) HSD17B10KDM4ETP53SMN1; SMN2ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2008118790-A1 DIHYDROINDAZOLE COMPOUNDS USEFUL IN TREATING IRON DISORDERS XENON PHARMACEUTICALS INC. (CA) 2008-10-02 WO disclosed
US-20080234327-A1 DIHYDROINDAZOLE COMPOUNDS USEFUL IN TREATING IRON DISORDERS XENON PHARMACEUTICALS INC. (CA) 2008-09-25 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080234327-A1 DIHYDROINDAZOLE COMPOUNDS USEFUL IN TREATING IRON DISORDERS FECH, SLC40A1, HAMP HSD17B10 584/4885KDM4E 2577/4885TP53 2762/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.